Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Accumulated Expenses (2016 - 2026)

Collegium Pharmaceutical has reported Accumulated Expenses over the past 11 years, most recently at $62.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 13.39% year-over-year to $62.5 million; the TTM value through Dec 2025 reached $62.5 million, down 13.39%, while the annual FY2025 figure was $62.5 million, 13.39% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $62.5 million at Collegium Pharmaceutical, up from $2.9 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $72.1 million in Q4 2024 and troughed at $968000.0 in Q1 2024.
  • A 5-year average of $13.0 million and a median of $2.9 million in 2023 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: soared 2836.46% in 2024 and later tumbled 93.94% in 2025.
  • Year by year, Accumulated Expenses stood at $3.2 million in 2021, then crashed by 33.89% to $2.1 million in 2022, then soared by 134.13% to $5.0 million in 2023, then skyrocketed by 1346.24% to $72.1 million in 2024, then decreased by 13.39% to $62.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for COLL at $62.5 million in Q4 2025, $2.9 million in Q3 2025, and $14.0 million in Q2 2025.